4,901 trials
Muscular Atrophy, Spinal
Primary: Part 1: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Risdiplam and Its Metabolite (M1) — 792; 987; 222; 263 h*ng/mL
Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for Phenylacetate, Benzoate, and Their Metabolites (Phenylacetylglutamine and Hippurate) — 300.7; 233.2; 69.77; 54.13…
Nonhematologic Neoplasms, Advanced
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) Assessed by National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Version 4.03…
Stroke
Primary: Change From Baseline in Forward Propulsion of the Paretic Limb From Pre- to Post-intervention — 0.00 Newtons . seconds/Body Weight — p=0.77
HIV Infection · Erythrocyte Glutathione Deficiency
Primary: Muscle Glutathione Concentration — 0.5; 2.2 micromol/g.Hb
Renal Impairment
Primary: Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Lorlatinib — 8329; 8683; 9890; 11760 ng*hr/mL
Lymphoma · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Maximum Tolerated Dose (MTD) — 20; 100 milligrams
Influenza · Vaccine
Primary: Number of Participants With Solicited Local Reactions Within 7 Days Following Each Vaccination — 10; 2; 0; 11 Participants
Cancer, Solid Tumor
Primary: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Metastatic Cancer · Solid Tumor · Lymphoma
Primary: Assessment of Treatment Related Adverse Events (AEs). — 0; 0; 0; 1 Patients with any DLT
Healthy
Primary: Area Under the Concentration-time Curve of BI 425809 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) — 11815.37; 10944.06 nanomoles * hours per…
Tumors
Primary: Dose-Escalation Phase: Maximum Tolerated Dose (MTD) of Mirvetuximab Soravtansine — 6.0; 2.0 mg/kg
Neoplasm
Primary: Part A: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 1; 4; 1…
First-line Treatment for Patients With Non-resectable Gastric Cancer or Cancer of the Esophagus or
Primary: Median Overall Survival — 4.3; 13.8; 14.6; 15.2 Months
Obesity
Primary: Number of Subjects With Adverse Events (AEs) — 2; 5; 3; 2 Participants